Top of this page
Skip navigation, go straight to the content
Discover how we are connecting patients, people and science in new ways to make breakthroughs in severe diseases
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of € 3.2 billion in 2010.
Many companies claim to be patient-driven, but for UCB it is a living reality. In fact, we do not think of people with severe diseases as "patients" but as individuals with lives beyond their disease.
‘Closing the Gap’ at Christmas time
Posted by Isabelle de Cambry, Corporate Social Responsibility 21-Dec-2011
UCB: always listening
Posted by France Nivelle, Global Communications & Change Support 06-Dec-2011
Posted by Nicolas Tièche, Coordination Mgr Bioplant Switzerland 05-Dec-2011